GleamWall
中文EN

CNBX CNBX Pharmaceuticals Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1343009 · Fiscal year ends 08/31

Financial factors as of 2026-02-28 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,121.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets17,104.8%
Debt / equity—
Current ratio0.01x
Interest coverage-6.65x

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-638.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-05-312026Q22026-02-282026Q12025-11-302025Q4*2025-08-312025Q32025-05-312025Q22025-02-282025Q12024-11-302024Q4*2024-08-31
Income statement
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0——$0$0——
Gross profit$0$0——$0$0——
R&D expense—$0$0$0$0$0$0-$73,934
SG&A expense$162,763$72,963$64,002$129,731$40,380$64,743$36,837$126,468
Operating income-$162,763-$72,963-$64,002-$129,731-$40,380-$64,743-$36,837-$52,533
Interest expense—-$32,621$46,296$18,340$14,166$4,191$3,122—
Net income-$154,165-$44,098-$113,719-$150,109-$59,727-$69,788-$34,352-$60,584
EBITDA——-$64,002-$129,731-$40,380-$64,743-$36,837-$52,533
EPS (basic)0.000.000.00—0.000.00-0.00—
EPS (diluted)0.000.000.00—0.000.00-0.00—
Weighted avg. shares (diluted)1.32B931.02M732.86M—42.60M32.10M31.11M—
Balance sheet
Cash & equivalents$9,487$12,154$7,703$15,111$13,648$45,675$17,339$26,416
Current assets$12,795$14,899$11,162$18,437$18,615$50,660$22,308$31,383
PP&E, net$0$0$0$0$0$0$0$0
Total assets$12,795$14,899$11,162$18,437$18,615$50,660$22,308$31,383
Current liabilities$2.67M$2.55M$2.58M$2.51M$2.56M$2.62M$2.54M$2.51M
Short-term debt$120,000$75,000—$0————
Total liabilities$2.67M$2.55M$2.58M$2.51M$2.56M$2.62M$2.54M$2.51M
Shareholders' equity-$2.66M-$2.53M-$2.57M-$2.50M-$2.54M-$2.57M-$2.51M-$2.48M
Shares outstanding1.48B1.13B753.20M553.96M92.51M33.86M31.11M31.11M
Cash flow statement
Operating cash flow-$47,667-$30,549-$47,408-$28,545-$52,019-$51,664-$39,077-$48,250
Investing cash flow——$0$0$0$0$0$0
Financing cash flow$45,000$35,000$40,000$30,008$19,992$80,000$30,000$1,260
Depreciation & amortization——$0$0$0$0$0$0
Stock-based compensation——$0$0$0$0$0$34,975

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.